Therapeutic Asset Ratings

130 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Fludarabine Head and Neck Squamous Cell Carcinoma	Beijing Biotech	P1/2	CCC (49)
FLUDEOXYGLUCOSE Head and Neck Squamous Cell Carcinoma	Anusha Kalbasi	P1/2	CCC (49)
TRASTUZUMAB Head and Neck Squamous Cell Carcinoma	Fate Therapeutics	P1/2	CCC (49)
Dacomitinib Head and Neck Squamous Cell Carcinoma	National Cancer Centre, Singapore	P2	CCC (48)
Fianlimab Head and Neck Squamous Cell Carcinoma	Regeneron Pharmaceuticals	P2	CCC (48)
hs-20093 Head and Neck Squamous Cell Carcinoma	Hansoh BioMedical R&D Company	P2	CCC (48)
Pd-L1 T-Hank Head and Neck Squamous Cell Carcinoma	ImmunityBio, Inc.	P2	CCC (48)
Selvigaltin Head and Neck Squamous Cell Carcinoma	Providence Health & Services	P2	CCC (48)
Si-B003 Head and Neck Squamous Cell Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (48)
Tirelizumab Head and Neck Squamous Cell Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (48)
tj107 Head and Neck Squamous Cell Carcinoma	TJ Biopharma Co., Ltd.	P2	CCC (48)
vv1 Head and Neck Squamous Cell Carcinoma	Vyriad, Inc.	P2	CCC (48)
Cediranib Head and Neck Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1	CCC (48)
Spartalizumab Head and Neck Squamous Cell Carcinoma	SOLTI Breast Cancer Research Group	P2	CC (46)
FULVESTRANT Head and Neck Squamous Cell Carcinoma	Terremoto Biosciences Inc.	P1/2	CC (46)
Obinutuzumab Head and Neck Squamous Cell Carcinoma	Simcha IL-18, Inc.	P1/2	CC (46)
n-803 Head and Neck Squamous Cell Carcinoma	ImmunityBio, Inc.	P2	CC (42)
[111in]-fpi-1967 Head and Neck Squamous Cell Carcinoma	Fusion Pharmaceuticals Inc.	P1/2	CC (41)
[225Ac]-FPI-1966 Head and Neck Squamous Cell Carcinoma	Fusion Pharmaceuticals Inc.	P1/2	CC (41)
Ale.P02 Head and Neck Squamous Cell Carcinoma	Alentis Therapeutics AG	P1/2	CC (41)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Head and Neck Squamous Cell Carcinoma	NKGen Biotech, Inc.	P1/2	CC (41)
Amt-116 Car-T Cells Head and Neck Squamous Cell Carcinoma	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1/2	CC (41)
Amt-253 Car-T Cells Head and Neck Squamous Cell Carcinoma	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1/2	CC (41)
azd6750 Head and Neck Squamous Cell Carcinoma	AstraZeneca	P1/2	CC (41)
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)- Head and Neck Squamous Cell Carcinoma	VM Oncology, LLC	P1/2	CC (41)

Showing 26 to 50 of 130 assets

PreviousPage 2 of 6Next